Skip to content

Rapid Detection of COVID-19 by Portable and Connected Biosensor : Biological Proof of Concept

Rapid Detection of COVID-19 by Portable and Connected Biosensor : Biological Proof of Concept

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04780334
Acronym
COR-DIAL-S
Enrollment
200
Registered
2021-03-03
Start date
2021-07-07
Completion date
2022-05-02
Last updated
2024-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19, SARS-CoV Infection

Brief summary

The main objective of this CorDial-S proof-of-concept study is to evaluate the ability to detect COVID-19 infection in nasopharyngeal swabs with CorDial-S and compare it to the PCR technique currently in use. Saliva analysis will be the subject of secondary analysis. The CorDial-S medical device could allow the specimens to be analyzed using a small portable device and the results to be returned in minutes to the medical team and the patient, and communicated in real time with a telemedicine and remote monitoring system to the health authorities to allow the necessary protective, containment and therapeutic management measures to be put in place if necessary. The benefits would be 1. greater sensitivity 2. a great speed because 8tests could be performed at the same time with a result in a few minutes 3. a very high specificity at least equivalent to PCR. This new diagnostic strategy could become extremely valuable in the fight against COVID-19, especially in the case of very long-term persistence and incomplete vaccination of the French and foreign population.

Interventions

DIAGNOSTIC_TESTCOVID-19 RT-PCR

Nasopharyngeal swabs for COVID-19 RT-PCR

DIAGNOSTIC_TESTBiosensor

Portable and Connected Biosensor viral

Sponsors

University Hospital, Lille
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Male or female or child without age limit * Admitted to a Reference Health Establishment (RHS) in an emergency unit, hospitalization or intensive care unit for suspicion of SARS-CoV-2 infection regardless of clinical presentation and degree of severity. * Patient to be diagnosed by PCR test on nasopharyngeal swab. * Social insured

Exclusion criteria

* Refusal of the person to participate (collection of information, second use of his sample, collection of saliva by spitting) * Pregnant and breastfeeding women * Protected Majors

Design outcomes

Primary

MeasureTime frame
Sensitivity and specificity of CorDial-S based on the first nasopharyngeal swab taken on patient admission, compared to the final positive or negative diagnosis of COVID-19 by the medical teamat patient admission (Baseline)

Secondary

MeasureTime frame
Cohen's Kappa Coefficient for concordance for the diagnosis of CoV-2-SARS between PCR and CorDial-S based on nasopharyngeal swabs taken at patient admission.at patient admission (Baseline)
Sensitivity and specificity of CorDial-S based on the first saliva sample taken at patient admission compared to the final positive or negative diagnosis of COVID-19 by the medical team.at patient admission (Baseline)
Cohen's Kappa Coefficient for concordance for the diagnosis of CoV-2-SARS between PCR and CorDial-S based on saliva samples taken at patient admission.at patient admission (Baseline)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026